These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22153696)

  • 1. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Quon MJ; Shin KC; Lim S; Lee Y; Sakuma I; Lee K; Han SH; Shin EK
    Atherosclerosis; 2012 Feb; 220(2):537-44. PubMed ID: 22153696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
    Koh KK; Oh PC; Sakuma I; Lee Y; Han SH; Shin EK
    Int J Cardiol; 2016 Oct; 221():342-6. PubMed ID: 27424313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia.
    Oh PC; Koh KK; Sakuma I; Lim S; Lee Y; Lee S; Lee K; Han SH; Shin EK
    Int J Cardiol; 2014 Oct; 176(3):696-702. PubMed ID: 25147070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
    Koh KK; Han SH; Quon MJ; Yeal Ahn J; Shin EK
    Diabetes Care; 2005 Jun; 28(6):1419-24. PubMed ID: 15920062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
    Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
    Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
    Capell WH; DeSouza CA; Poirier P; Bell ML; Stauffer BL; Weil KM; Hernandez TL; Eckel RH
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):307-13. PubMed ID: 12588776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
    Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
    Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
    J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Effects of Omega-3 Fatty Acids on Insulin Resistance and Lipid Profile in Maintenance Hemodialysis Patients: a Randomized Placebo-Controlled Trial.
    Gharekhani A; Dashti-Khavidaki S; Lessan-Pezeshki M; Khatami MR
    Iran J Kidney Dis; 2016 Sep; 10(5):310-318. PubMed ID: 27721230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
    Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
    Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
    Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: Randomized, double-blind, placebo-controlled trial.
    Samimi M; Jamilian M; Asemi Z; Esmaillzadeh A
    Clin Nutr; 2015 Jun; 34(3):388-93. PubMed ID: 24973862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.